目的探讨经脑动脉内注溶栓药物治疗急性闭塞性脑血管病的临床效果。
Objective To evaluate the value of intra arterial thrombolytic therapy in the treatment of acute occlusive cerebral disease.
随着急性心肌梗死发病率的逐年上升，新的溶栓药物正在不断的研制中。
With the increase in the morbidity of acute myocardial infarction, new thrombolytics are continually developed.
目的：介绍急性心肌梗死溶栓药物的研发进展，并评价其临床疗效和安全性。
OBJECTIVE: To introduce the research and development of thrombolytic drugs for AMI, and evaluate their clinical efficacy and safety.
脂质体作为溶栓药物载体，经RGDS修饰后，具有较好的靶向性抗血栓作用。
The results show liposomes as the carrier of medicine has better target anti-thrombus effect after RGDS modifies it.
与传统的一些溶栓药物相比，纳豆激酶具有安全性好、成本低及可以口服等优点。
Compared with other medicines which have some attractive traits, for example good safety factor, low cost and can take it orally.
目的建立一种用于体外溶栓活性精确定量分析和高通量溶栓药物筛选鉴定的方法。
OBJECTIVE To establish a method for detecting and analyzing fibrinolysis activity in vitro and high throughput screening fibrinolysis drugs.
目的观察股动脉穿刺注射扩张血管及溶栓药物治疗下肢远端动脉缺血患者的临床疗效。
Objective To investigate the effects of vascular vasodilation via femoral artery puncture combined with thrombolytics on arterial ischemia of the lower extremity.
目的探讨重症颅内静脉窦血栓形成血管内治疗方法的选择、溶栓药物的使用及其疗效和安全性。
Objective To explore how to select the ways of endovascular treatment for serious cranial venous sinus thrombosis, and how to use the thrombolytic, and to evaluate the curative effect and risk.
以溶栓药物的临床试验为例，说明在优效试验、等效试验及非劣效试验中疗效相等的基本概念。
This article takes thrombolytic therapy as examples to clarify ideas and to interpret the general concepts of an equivalence in a superiority trial, a equivalence trial and a non-inferiority trial.
是否治疗的决定应由参与会诊的眼科医生作出，具体措施包括手术减压，纤溶或溶栓药物，全身甾体激素治疗以及血液稀释疗法。
The decision to institute treatment should be left to the consulting ophthalmologist and may include surgical decompression, fibrinolytic or thrombolytic agents, systemic steroids, and hemodilution.
究其原因主要是由于超早期诊断困难，溶栓及神经保护治疗的个体时间窗不明和缺乏特效的药物。
The reason lies in the difficulty of super early diagnosis, insensibility of the window time of nerve protective therapy, dissolution of thrombus and absence of special effective drugs.
文章对动脉内溶栓治疗的时间窗、治疗前评价、病例和药物选择等研究现状做了综述。
This article reviews the study status quo of the time window, pretreatment assessment, and selection of patients and drugs for intra-arterial thrombolysis.
文章对新型溶血栓药物及溶栓辅助药的研制进展和临床应用现状进行了综述。
Here reviewed were recent progress in research and current events of clinical application of recombinant thrombolytic agents and thrombolytic adjuvant.
由于现用溶栓药或多或少都有一些缺陷，因此人们一直都在研制开发新型的溶血栓药物。
Because most of the using thrombolytics have defect, it is necessary to develop new thrombolytics.
其中1例通过药物溶栓获得再通，4例通过原切口行内瘘重建获得再通，累计次级通畅率为99.1%（111/112）。
Re-opening of FAVF was achieved in 1 case by local urokinase thrombolysis and in the other 4 cases by reconstruction of the fistula. The secondary patency rate reached 99.1%(111112).
结论肝动脉介入溶栓治疗为HAT的有效方法，留置肝动脉导管持续药物泵入溶栓效果显著。
Conclusion Intraarterial thrombolytic therapy may be a promising method in the treatment of HAT. Transcatheter hepatic arterial thrombolysis shows a significant result.
结论肝动脉介入溶栓治疗为HAT的有效方法，留置肝动脉导管持续药物泵入溶栓效果显著。
Conclusion Intraarterial thrombolytic therapy may be a promising method in the treatment of HAT. Transcatheter hepatic arterial thrombolysis shows a significant result.
应用推荐